Delivery Order SPE2DB20D2104-SPE2DB25FMTPH
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,563.86 to AmerisourceBergen Drug Corp for the supply of Yuvafem 10 mcg vaginal inserts (18-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 4, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $6,444.10 for Yuvafem 10 microgram vaginal insert (18 units) on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's extensive pharmaceutical supply relationship with DLA and carries no set-aside designation. The product will be performed and delivered from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,093.79 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (18 count) on November 6, 2025, with an ultimate completion date of November 7, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,054.25 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (8-count package) on October 22, 2025, with completion targeted for October 23, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999.999 billion and runs through December 2026. The product...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,004.41 to AmerisourceBergen Drug Corp for the supply of Yuvafem 10 MCG Vaginal Insert (8 count). The award, issued on September 12, 2025, represents a firm fixed-price contract with an ultimate completion date of September 15, 2025. This is a non-set-aside competitive award, and performance will occur at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Yuvafem 10 micrograms vaginal inserts (18 units) under a firm fixed-price contract valued at $1,741.75. This is a non-set-aside competitive award with an ultimate completion date of August 12, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued as a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,396.56 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (18 count) on November 6, 2025, with an ultimate completion date of November 7, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $28,600.86 to AmerisourceBergen Drug Corp for the supply of Yuvafem 10 mcg vaginal inserts (18 count) on August 20, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,209.68 to AmerisourceBergen Drug Corp for Yuvafem 10 microgram vaginal inserts (18 count) on August 21, 2025, with completion expected by August 22, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal insert (18 count) on September 9, 2025, with a ceiling value of $5,474.57 and ultimate completion date of September 10, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMTPHDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,568.22 to AmerisourceBergen Drug Corp for Yuvafem 10 mcg vaginal inserts (18 count) on June 18, 2025, with completion scheduled for June 20, 2025. This firm fixed-price, non-set-aside delivery order was fulfilled at the vendor's Conshohocken, Pennsylvania location. The award represents a routine pharmaceutical supply transaction supporting federal medical procurement needs within DLA's supply chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard, supplying a diverse portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's track record of competitively awarded contracts demonstrates its capability to meet federal procurement requirements for specialized pharmaceutical products.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 6/18/25 |